CAJ | 학술논문

目的：探讨胃癌根治术后患者血清HIF-1α、VEGF-A、CEA和CA19-9表达水平与胃癌临床病理特征、复发转移的关系。方法：采用回顾性的方法，对2010年1月至2012年9月于我院行胃癌根治术患者病历进行抽取，共计76例患者。对患者辅助化疗前后、随访截止前最近一次复诊时/复发转移时血清HIF-1α、VEGF-A、CEA和CA19-9的浓度进行整理与分析。结果：76例患者辅助化疗前后血清HIF-1α、VEGF-A、CEA和CA19-9表达水平之间的差异无统计学意义（P>0.05）。35例复发转移患者复发转移时血清HIF-1α、CEA浓度较辅助化疗前升高，差异有统计学意义（P <0.05）。35例患者复发转移时血清HIF-1α、CEA浓度较41例未复发转移患者随访截止前最近一次复诊时升高，差异有统计学意义（P<0.05）。亚组分析示31例血清CEA浓度维持在正常水平的患者，12例复发转移患者的血清HIF-1α浓度较19例未复发转移患者明显升高（P=0.022）。结论：胃癌根治术后患者复发转移时血清HIF-1α、CEA浓度升高；CEA浓度在正常范围内的患者，复发转移时血清HIF-1α浓度升高，提示根治术后患者血清HIF-1α浓度的动态升高可能预示胃癌复发转移。
목적：탐토위암근치술후환자혈청HIF-1α、VEGF-A、CEA화CA19-9표체수평여위암림상병리특정、복발전이적관계。방법：채용회고성적방법，대2010년1월지2012년9월우아원행위암근치술환자병력진행추취，공계76례환자。대환자보조화료전후、수방절지전최근일차복진시/복발전이시혈청HIF-1α、VEGF-A、CEA화CA19-9적농도진행정리여분석。결과：76례환자보조화료전후혈청HIF-1α、VEGF-A、CEA화CA19-9표체수평지간적차이무통계학의의（P>0.05）。35례복발전이환자복발전이시혈청HIF-1α、CEA농도교보조화료전승고，차이유통계학의의（P <0.05）。35례환자복발전이시혈청HIF-1α、CEA농도교41례미복발전이환자수방절지전최근일차복진시승고，차이유통계학의의（P<0.05）。아조분석시31례혈청CEA농도유지재정상수평적환자，12례복발전이환자적혈청HIF-1α농도교19례미복발전이환자명현승고（P=0.022）。결론：위암근치술후환자복발전이시혈청HIF-1α、CEA농도승고；CEA농도재정상범위내적환자，복발전이시혈청HIF-1α농도승고，제시근치술후환자혈청HIF-1α농도적동태승고가능예시위암복발전이。
Objective: To explore the correlation among the serum concentrations of HIF-1α, VEGF-A, CEA, CA19-9, the patients' clinicopathological features, recurrence or metastasis in gastric cancer patients after curative resection. Methods: Using retrospective method, a total of 76 cases of gastric cancer patients after radical surgery from January 2010 to September 2012 in our department were extracted. The serum concentrations of HIF-1α, VEGF-A, CEA and CA19-9 were analyzed before and after adjuvant chemotherapy, at the last visit before follow-up deadline/the occurrence of recurrence or metastasis. Results: There were no signiifcant differences in the concentrations of HIF-1α, VEGF-A, CEA and CA19-9 before and after adjuvant chemotherapy in 76 patients (P>0.05). The concentrations of HIF-1αand CEA of 35 gastric cancer patients increased signiifcantly after recurrence or metastasis compared with those before adjuvant chemotherapy (P<0.05). The concentrations of HIF-1αand CEA of 35 gastric cancer patients with recurrence or metastasis was signiifcantly higer than those of 41 patients without recurrence or metastasis at the last visit before follow-up deadline (P<0.05). The subgroup analysis showed that among 31 patients with normal CEA level, serum HIF-1αlevels of with 12 patients recurrence or metastasis was signiifcantly higher than those of 19 patients without recurrence or metastasis (P=0.022). Conclusion: The serum levels of HIF-1αand CEA of gastric cancer patients increased after recurrence or metastasis. For the patients with normal CEA level, the serum level of HIF-1α increased after recurrence or metastasis, which indicated that the increase of HIF-1αwould predict the patients' recurrence or metastasis in gastric cancer.